
Prostate Cancer
Latest News
Latest Videos

CME Content
More News

The prostate cancer drug abiraterone acetate is expected be provided for patients through England's publicly funded healthcare system after NICE reversed its initial recommendation.

Dr. Andrew Goy, from John Theurer Cancer Center, on Neoadjuvant Hormonal Therapy Plus Zytiga

Combined neoadjuvant treatment with abiraterone acetate (Zytiga) plus standard hormonal therapy before prostatectomy eradicated or nearly eradicated tumors in 34% of patients with localized high-risk prostate cancer.

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, on Neoadjuvant Hormonal Therapy Combined With Abiraterone Acetate

Now, with four new agents approved in the last two years and two promising agents in the pipeline, therapy selection and potential outcomes are changing.

Men with low-risk prostate cancer who have opted for active surveillance are about half as likely to experience pathologic progression or abandon active surveillance if they take a 5-ARI.

The neoadjuvant administration of sipuleucel-T may stimulate an immune response in patients with localized prostate cancer without adversely affecting their surgeries.

Dr. Robert Dreicer, from the Cleveland Clinic, on Utilizing New Prostate Cancer Therapies

Dutasteride may postpone disease progression in men with low-risk prostate cancer who have opted for an active surveillance strategy.

Nurses play vital roles in assuring that patients with metastatic castration-resistant prostate cancer (mCRPC) are optimally treated with sipuleucel-T.

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Discusses PSA Velocity

Coronary artery disease and prostate cancer have been shown to share several modifiable and nonmodifiable risk factors including age, race, family history, and possibly diet.

Dr. Daniel Petrylak, from the Herbert Irving Comprehensive Cancer Center, Discusses the Future of Abiraterone Acetate

Dr. Oliver Sartor, from Tulane Cancer Center, Discusses a New Trial Combining Radium-223 and Provenge

Dr. Howard Sandler, from Cedars-Sinai Medical Center, Describes the RTOG 9408 Prostate Cancer Trial Results

Dr. Leonard Gomella, from Jefferson Kimmel Cancer Center, Examines the Understating of Provenge Benefits

The paradigm of "more energy is better" is not limited to space travel, and in fact is center stage in a growing debate in the field of radiation oncology.

A further analysis of clinical trial data for sipuleucel-T suggests that it may have delivered a greater OS benefit than previously described.

Dr. Robert Dreicer, from the Cleveland Clinic, Discusses Sequencing MDV3100 and Abiraterone

The Trials in Progress section supplies summaries of ongoing research in a broad range of cancer types.

Dr. Leonard Gomella, from the Jefferson Kimmel Cancer Center, on Helping Patients Make Informed Medical Decisions

Dr. David Crawford, from University of Colorado Health Sciences Center, Discusses Transperineal 3D Mapping Biopsy

The keynote address at the ASCO Genitourinary Cancers Symposium highlighted a collaborative effort to develop a comprehensive molecular classification of prostate cancer.

Dr. Daniel Petrylak, from Columbia University Medical Center, Discusses Chemotherapy in Prostate Cancer

Targeting the bone microenvironment appears to be a potential approach to treating prostate cancer.

























































